AMAG

AMAG Pharmaceuticals (AMAG)   announced a study of its drug    Feraheme  (ferumoxytol) that  makes it an acquisition candidate. New  study from   a  head-to-head trial comparing Feraheme  Injection for intravenous  use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease is positive for AMAG  Pharmaceuticals.